Voss Capital, LLC Cue Biopharma, Inc. Transaction History

Voss Capital, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$2.39 - $3.95 $179,250 - $296,250	-75,000 Reduced 37.5%	125,000 $356,000
Q3 2022 Nov 02, 2022	BUY	$2.23 - $3.37 $223,000 - $337,000	100,000 Added 100.0%	200,000 $446,000
Q2 2022 Aug 09, 2022	BUY	$2.49 - $5.92 $249,000 - $592,000	100,000 New	100,000 $249,000
Q3 2021 Nov 16, 2021	SELL	$10.06 - $15.3 $1.26 Million - $1.91 Million	-125,000 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$10.9 - $14.53 $272,500 - $363,250	25,000 Added 25.0%	125,000 $1.46 Million
Q1 2021 May 17, 2021	SELL	$11.2 - $16.09 $1.35 Million - $1.94 Million	-120,714 Reduced 54.69%	100,000 $1.22 Million
Q4 2020 Feb 12, 2021	SELL	$11.12 - $16.4 $65,152 - $96,087	-5,859 Reduced 2.59%	220,714 $2.76 Million
Q3 2020 Nov 12, 2020	BUY	$15.05 - $23.54 $2.77 Million - $4.33 Million	183,773 Added 429.38%	226,573 $3.41 Million
Q2 2020 Aug 13, 2020	SELL	$12.7 - $30.73 $582,549 - $1.41 Million	-45,870 Reduced 51.73%	42,800 $1.05 Million
Q1 2020 May 15, 2020	SELL	$9.85 - $22.27 $37,725 - $85,294	-3,830 Reduced 4.14%	88,670 $749,000
Q4 2019 Feb 14, 2020	BUY	$7.06 - $17.47 $653,050 - $1.62 Million	92,500 New	92,500 $1.47 Million

14.1M

14.4K

2.6K

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $38.2M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

Get notified when there are updates to the investment portfolio of Voss Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Voss Capital, LLC with notifications on news.